MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions
Endometrial Neoplasms
Interventions
DIAGNOSTIC_TEST

next generation sequencing AND Immunohistochemical examination

First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.

Trial Locations (1)

350014

Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
collaborator

Fujian Provincial Hospital

OTHER

collaborator

First Affiliated Hospital of Fujian Medical University

OTHER

collaborator

Gutian Hospital

UNKNOWN

lead

Fujian Cancer Hospital

OTHER_GOV

NCT06126393 - MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer | Biotech Hunter | Biotech Hunter